This week, there are 16 drugs in the patent and exclusivity list. They are: - Yupelri by Mylan Ireland Ltd, containing active ingredient Revefenacin - Xiidra by Bausch and Lomb Inc, containing active ingredient Lifitegrast - Ogsiveo by Springworks Therapeutics Inc, containing active ingredient Nirogacestat Hydrobromide - Koselugo by AstraZeneca Pharmaceuticals LP, containing active ingredient Selumetinib Sulfate - Mektovi by Array Biopharma Inc, containing active ingredient Binimetinib - Viberzi by AbbVie Inc, containing active ingredient Eluxadoline - Lynparza by AstraZeneca Pharmaceuticals LP, containing active ingredient Olaparib Read More

This week, there are 11 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's XIIDRA, containing active ingredient LIFITEGRAST - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - MYLAN SPECIALTY LP's TOBI PODHALER, containing active ingredient TOBRAMYCIN - ASTRAZENECA LP's SYMBICORT, containing active ingredient BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - ASTRAZENECA AB's BYETTA, containing active ingredient EXENATIDE SYNTHETIC - HOFFMANN-LA ROCHE INC's ALECENSA, containing active ingredient ALECTINIB HYDROCHLORIDE - HOFFMANN LA ROCHE INC's ZELBORAF, containing active ingredient VEMURAFENIB - GISKIT PHARMA BV's EXEM FOAM KIT, containing active ingredient AIR POLYMER-TYPE A - MERCK SHARP AND DOHME CORP's PREVYMIS, containing active ingredient LETERMOVIR - MERCK SHARP AND DOHME LLC's PREVYMIS, containing active ingredient LETERMOVIR - BRISTOL MYERS SQUIBB CO's SPRYCEL, containing active ingredient DASATINIB Read More